Table 1. Eligibility Status.
| Criteriaa | No. (%) | ||
|---|---|---|---|
| Etanercept (n = 1509) |
Adalimumab (n = 4000) |
Ustekinumab (n = 1627) |
|
| Eligible | 839 (56) | 2219 (56) | 754 (46) |
| Insufficient baseline PASI only | 158 (10)b | 1166 (29)c | 370 (23)c |
| Missing baseline PASI only | 145 (10) | 333 (8) | 109 (7) |
| Ineligible | 367 (24) | 282 (7) | 394 (24) |
| Age <18 y | 6 (<1) | 19 (<1) | 5 (<1) |
| Nonchronic plaque psoriasis | 86 (6) | 157 (4) | 75 (5) |
| Comorbiditiesd | |||
| Psychiatric | 43 (3) | NA | 51 (3) |
| Myocardial infarction | 2 (<1) | NA | 10 (<1) |
| Angina | 47 (3) | NA | 62 (4) |
| Diabetes/endocrine | 143 (9) | NA | 201 (12) |
| Hypertension | 89 (6) | NA | NA |
| Renal | NA | 9 (<1) | 4 (<1) |
| Gastrointestinal | NA | 22 (<1) | 13 (1) |
| Blood/laboratory values | NA | 6 (<1) | NA |
| Infections | |||
| Recent | 7 (<1) | NA | 6 (<1) |
| HIV/HBV/HCV | 2 (<1) | 6 (<1) | 1 (<1) |
| Latent TB | NA | 39 (1) | 23 (1) |
| Cancers | 8 (<1) | 28 (1) | 2 (<1) |
| Two or more ineligibility criteria | 60 (4) | 7 (<1) | 58 (4) |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NA, not applicable; TB, tuberculosis.
a
No exclusions based on prior exposure to therapies targeting tumor necrosis factor-α (etanercept; adalimumab) or interleukin 12/23 (ustekinumab).
b
Baseline PASI values of less than 10.
c
Baseline PASI values of less than 12.
d
No reports of multiple sclerosis, congestive heart failure, hepatic, or pulmonary disorders as comorbidities.